PDCD1LG2 and ovarian carcinoma: Several clinical trials are ongoing at the moment, according to the ClinicalTrials.gov database [accessed July 06, 2019], testing anti-PD-1/PD-L1 blockade alone or in combination in patients with endometrial, cervical, vulvar and ovarian cancer, while there are no ongoing clinical trials using anti-PD-L2 (Tables 1–3).